论文部分内容阅读
目的监测急性脑梗死患者应用东菱克栓酶治疗过程中,纤维蛋白原(FIB)水平,观察用药后血浆中纤维蛋白原(FIB)水平下降情况。方法选择急性脑梗死患者90例,其中测试组60例,对照组30例,应用Sysmex CA-1500型自动血液凝血分析仪进行血浆纤维蛋白原(FIB)测定。结果 60例急性脑梗死患者用药前与用药后第一天、用药后第一天与用药后第二天纤维蛋白原(FIB)水平差异有统计学意义(P<0.01),用药后第二天与用药后第三天纤维蛋白原(FIB)水平差异有统计学意义(P<0.05),对照组用药前与用药后血浆纤维蛋白原(FIB)水平均差异无统计学意义(P>0.05)。结论应用东菱克栓酶对脑梗死进行治疗,对降低患者血浆中纤维蛋白原(FIB)水平有着重要意义,要注意纤维蛋白原(FIB)水平的监测。
Objective To monitor the level of fibrinogen (FIB) in patients with acute cerebral infarction and to observe the decrease of plasma fibrinogen (FIB) level after treatment. Methods Ninety patients with acute cerebral infarction were selected, including 60 in the test group and 30 in the control group. Plasma Fibrinogen (FIB) was measured by Sysmex CA-1500 automatic blood coagulation analyzer. Results The levels of fibrinogen (FIB) in the 60 patients with acute cerebral infarction before treatment and on the first day after treatment, on the first day after treatment and on the second day after treatment were significantly different (P <0.01) (P <0.05). There was no significant difference in the levels of fibrinogen (FIB) before and after treatment between the two groups (P> 0.05) . Conclusion Treatment of cerebral infarction with tangling suppository is of great significance in reducing fibrinogen (FIB) level in plasma of patients and paying attention to the monitoring of fibrinogen (FIB) level.